Hunan Er-Kang Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Hunan Er-Kang Pharmaceutical's earnings have been declining at an average annual rate of -36.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 9.1% per year.
Key information
-36.3%
Earnings growth rate
-36.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.1% |
| Return on equity | -5.1% |
| Net Margin | -14.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hunan Er-Kang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,512 | -218 | 402 | 58 |
| 31 Dec 23 | 1,783 | -195 | 395 | 57 |
| 30 Sep 23 | 1,999 | 50 | 414 | 57 |
| 30 Jun 23 | 2,050 | 68 | 391 | 51 |
| 31 Mar 23 | 1,991 | 49 | 363 | 47 |
| 01 Jan 23 | 1,871 | 46 | 360 | 48 |
| 30 Sep 22 | 1,971 | -913 | 360 | 48 |
| 30 Jun 22 | 2,273 | -855 | 397 | 46 |
| 31 Mar 22 | 2,278 | -813 | 409 | 48 |
| 01 Jan 22 | 2,235 | -791 | 406 | 49 |
| 30 Sep 21 | 2,182 | 169 | 409 | 49 |
| 30 Jun 21 | 2,012 | 220 | 381 | 46 |
| 31 Mar 21 | 2,325 | 215 | 380 | 47 |
| 31 Dec 20 | 2,382 | 192 | 386 | 48 |
| 30 Sep 20 | 2,576 | 175 | 411 | 47 |
| 30 Jun 20 | 2,596 | 96 | 444 | 53 |
| 31 Mar 20 | 2,432 | 95 | 441 | 55 |
| 31 Dec 19 | 2,744 | 159 | 465 | 55 |
| 30 Sep 19 | 2,757 | 84 | 477 | 55 |
| 30 Jun 19 | 2,720 | 124 | 455 | 56 |
| 31 Mar 19 | 2,618 | 199 | 463 | 61 |
| 01 Jan 19 | 2,354 | 217 | 432 | 56 |
| 30 Sep 18 | 2,105 | 265 | 415 | 60 |
| 30 Jun 18 | 2,218 | 321 | 335 | 106 |
| 31 Mar 18 | 2,542 | 407 | 324 | 86 |
| 31 Dec 17 | 2,828 | 522 | 316 | 79 |
| 30 Sep 17 | 3,080 | 628 | 302 | 61 |
| 30 Jun 17 | 2,998 | 691 | 361 | 0 |
| 31 Mar 17 | 2,972 | 846 | 354 | 0 |
| 31 Dec 16 | 2,706 | 795 | 347 | 0 |
| 30 Sep 16 | 2,423 | 900 | 299 | 0 |
| 30 Jun 16 | 2,280 | 847 | 278 | 0 |
| 31 Mar 16 | 1,971 | 683 | 262 | 0 |
| 31 Dec 15 | 1,756 | 605 | 247 | 0 |
| 30 Sep 15 | 1,619 | 517 | 267 | 0 |
| 30 Jun 15 | 1,442 | 434 | 265 | 0 |
| 31 Mar 15 | 1,330 | 320 | 249 | 0 |
| 31 Dec 14 | 1,370 | 288 | 236 | 0 |
| 30 Sep 14 | 1,351 | 265 | 183 | 0 |
| 30 Jun 14 | 1,328 | 252 | 166 | 0 |
| 31 Mar 14 | 1,168 | 218 | 148 | 0 |
| 31 Dec 13 | 1,011 | 193 | 143 | 0 |
| 30 Sep 13 | 870 | 159 | 149 | 0 |
| 30 Jun 13 | 832 | 148 | 142 | 0 |
Quality Earnings: 300267 is currently unprofitable.
Growing Profit Margin: 300267 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300267 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare 300267's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300267 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 300267 has a negative Return on Equity (-5.08%), as it is currently unprofitable.